Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.

Liver function associated with metabolic syndrome risk

22 Mar 2017

The risk of metabolic syndrome (MS) is associated with liver function in a Chinese population. Age and gender influence this association, a new study shows.

The cross-sectional study involved 32,768 individuals (20,643 males) who self-reported as healthy. Those who had histories of liver disease, were taking medication that may affect liver function, were pregnant and had malignant diseases were excluded.

Levels of total bilirubin (TBIL), alanine aminotransferase (ALT), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), elevated triglycerides (TG), blood urea nitrogen (BUN), uric acid (UA), creatinine (Cr) and fasting glucose (FG) were measured.

Of the 32,768 patients, 10,654 (32.51 percent) had MS; 37.72 percent of males had MS compared to 23.65 percent of females (p<0.01). In both males and females, MS incidence showed an increasing trend with age until 45 to 55 years.

In males, age was positively associated with LDL, HDL, FG, Cr, BUN, TC, waist circumference (WC), systolic blood pressure (SBP) and diastolic blood pressure (DBP), and negatively correlated with gamma glutamyltransferase (GGT), ALT, TG and UA. In females, on the other hand, age was negatively correlated only with HDL.

Both males (odds ratio [OR], 0.814; 95 percent CI, 0.743 to 0.891; OR, 0.673; 0.613 to 0.739; p<0.01 for both) and females (OR, 0.761; 0.661 to 0.875; OR, 0.753; 0.653 to 0.867; p<0.01 for both) in the third and fourth TBIL quartiles, respectively, were at a lower risk of MS.

Conversely, both males (OR, 1.710; 1.546 to 1.892; OR, 2.438; 2.202 to 2.700; OR, 3.715; 3.335 to 4.138; p<0.01 for all) and females (OR, 1.730; 1.458 to 2.052; OR, 2.425; 2.048 to 2.871; OR, 3.027; 2.552 to 3.592; p<0.01 for all) in the second to fourth GGT quartiles were at a higher risk of developing MS. Finally, ALT and age quartiles also showed significant increases in the risk of MS.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Rachel Soon, 01 Jun 2016

The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.

15 Jun 2016
The use of empagliflozin when added to standard care was associated with slower progression of kidney disease and lower rates of clinically relevant renal events in patients with type 2 diabetes, according to a recent study.
Radha Chitale, 13 Jun 2016
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.